Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results

gan Passardi, Alessandro, Fanini, Francesca, Turci, Livia, Foca, Flavia, Rosetti, Paola, Ruscelli, Silvia, Casadei Gardini, Andrea, Valgiusti, Martina, Dazzi, Claudio, Marangolo, Maurizio
Cyhoeddwyd yn Oncologist (2017)

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

gan Zoli Wainer, Zumaglini Federica, Oliverio Giovanni, Pasquini Enzo, Dazzi Claudio, Dall'Agata Monia, Cecconetto Lorenzo, Passardi Alessandro, Nanni Oriana, Milandri Carlo, Frassineti Giovanni, Amadori Dino
Cyhoeddwyd 2008-10-01

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

gan Passardi, Alessandro, Cecconetto, Lorenzo, Dall'Agata, Monia, Dazzi, Claudio, Pasquini, Enzo, Oliverio, Giovanni, Zumaglini, Federica, Zoli, Wainer, Nanni, Oriana, Milandri, Carlo, Frassineti, Giovanni Luca, Amadori, Dino
Cyhoeddwyd 2008

Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR)

gan Chiadini, Elisa, Canale, Matteo, Delmonte, Angelo, Dazzi, Claudio, Casanova, Claudia, Capelli, Laura, Mariotti, Marita, Papi, Maximilian, Gamboni, Alessandro, Puccetti, Maurizio, Bravaccini, Sara, Dubini, Alessandra, Calistri, Daniele, Crinò, Lucio, Ulivi, Paola
Cyhoeddwyd yn J Thorac Dis (2018)

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

gan Gelsomino, Francesco, Tiseo, Marcello, Barbieri, Fausto, Riccardi, Ferdinando, Cavanna, Luigi, Frassoldati, Antonio, Delmonte, Angelo, Longo, Lucia, Dazzi, Claudio, Cinieri, Saverio, Colantonio, Ida, Sperandi, Francesca, Lamberti, Giuseppe, Brocchi, Stefano, Tofani, Lorenzo, Boni, Luca, Ardizzoni, Andrea
Cyhoeddwyd yn Br J Cancer (2020)

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

gan Gelsomino, Francesco, Tiseo, Marcello, Barbieri, Fausto, Riccardi, Ferdinando, Cavanna, Luigi, Frassoldati, Antonio, Delmonte, Angelo, Longo, Lucia, Dazzi, Claudio, Cinieri, Saverio, Colantonio, Ida, Sperandi, Francesca, Lamberti, Giuseppe, Brocchi, Stefano, Tofani, Lorenzo, Boni, Luca, Ardizzoni, Andrea
Cyhoeddwyd yn Br J Cancer (2021)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

gan Ulivi, Paola, Delmonte, Angelo, Chiadini, Elisa, Calistri, Daniele, Papi, Maximilian, Mariotti, Marita, Verlicchi, Alberto, Ragazzini, Angela, Capelli, Laura, Gamboni, Alessandro, Puccetti, Maurizio, Dubini, Alessandra, Burgio, Marco Angelo, Casanova, Claudia, Crinò, Lucio, Amadori, Dino, Dazzi, Claudio
Cyhoeddwyd yn Int J Mol Sci (2014)

Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-vo...

gan Brandes, Alba A., Franceschi, Enrico, Ermani, Mario, Tosoni, Alicia, Albani, Fiorenzo, Depenni, Roberta, Faedi, Marina, Pisanello, Anna, Crisi, Girolamo, Urbini, Benedetta, Dazzi, Claudio, Cavanna, Luigi, Mucciarini, Claudia, Pasini, Giuseppe, Bartolini, Stefania, Marucci, Gianluca, Morandi, Luca, Zunarelli, Elena, Cerasoli, Serenella, Gardini, Giorgio, Lanza, Giovanni, Silini, Enrico Maria, Cavuto, Silvio, Baruzzi, Agostino
Cyhoeddwyd yn Neurooncol Pract (2014)